 While eosinophils play a role in inflammation associated with asthma, the exact mechanism of mepolizumab is unknown.After subcutaneous injection, mepolizumab has an estimated bioavailability of 80% and reaches highest blood plasma concentrations after four to eight days.Like other antibodies, it is degraded by proteolytic enzymes.